Αποτελέσματα Αναζήτησης
Table 1 presents the estimated reimbursement amount for α 1 -antiprotease treatment per infusionwith the annual costs based on whether infusion was administered weekly (at a dose of 60 mg/kg > 1 h) or monthly (at a dose of 250 mg/kg>4 h).
To assess the direct medical costs of having a1-antitrypsin deficiency, the current study surveyed members of the Alpha One Foundation Registry for Individuals with a1-Antitrypsin Deficiency to assess the annual expenditures by affected individuals for treating this disease.
The annual total health-care costs were high (mean range, $36,471 to $46,114; median range, $12,485 to $37,100 [according to the method for managing missing data]) for AAT deficiency. The total costs for individuals with the PI*ZZ phenotype exceeded those for individuals with a non-PI*ZZ phenotype.
17 Αυγ 2024 · Select appropriate treatment options for alpha-1 antitrypsin deficiency, such as augmentation therapy, bronchodilators, glucocorticoids, or liver transplantation, based on the patient's clinical status, disease progression, and response to previous interventions.
8 Απρ 2020 · Alpha1-antitrypsin (AAT) deficiency is one of the most common genetic diseases. Most persons carry two copies of the wild-type M allele of SERPINA1, which encodes AAT, and have normal...
For the 185 current alpha(1)-antiprotease users, the mean annual cost was $40,123 (median, $36,000). Conclusions: Annual health-care expenditures by individuals with alpha(1)-antitrypsin deficiency are very high, whether or not they are currently receiving augmentation therapy.
Current IV AAT therapy incurs significant annual healthcare costs, which exceed prior estimates reported in a 2003 study on cost effectiveness for patients with severe AATD. 23 In the US, AAT therapy costs an estimated US$82,000 per patient per year, excluding other out-of-pocket costs to the patient, such as visits to the physician and/or ...
